Sage Therapeutics, Inc.: 10-Q filed 2014-08-14
What Sage Therapeutics, Inc. reported in its quarterly report filed 2014-08-14 (fiscal Q2 2014): 26 published measures, 69 facts as tagged in accession 0001193125-14-310086.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-08-14
- Fiscal period
- fiscal Q2 2014
- Accession
- 0001193125-14-310086 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Sage Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 51,651,000 | USD | |
| At 2013-12-31 | 8,532,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 3,971,000 | USD | |
| At 2013-12-31 | 2,359,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | -44,792,000 | USD | |
| At 2013-12-31 | -31,536,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 49,127,000 | USD | |
| At 2013-12-31 | 8,066,000 | USD | |
| At 2013-06-30 | 523,000 | USD | |
| At 2012-12-31 | 2,802,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -6,192,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -11,982,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -4,655,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -8,044,000 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 5,000 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 3,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | -44,792,000 | USD | |
| At 2013-12-31 | -31,675,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 1,700,517 | shares | 91 |
| 2014-01-01 to 2014-06-30 | 1,676,864 | shares | 181 |
| 2013-04-01 to 2013-06-30 | 1,464,419 | shares | 91 |
| 2013-01-01 to 2013-06-30 | 1,442,774 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 1,700,517 | shares | 91 |
| 2014-01-01 to 2014-06-30 | 1,676,864 | shares | 181 |
| 2013-04-01 to 2013-06-30 | 1,464,419 | shares | 91 |
| 2013-01-01 to 2013-06-30 | 1,442,774 | shares | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 69,000 | USD | |
| At 2013-12-31 | 86,000 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -6,188,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -11,978,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -4,655,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -8,044,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 51,543,000 | USD | |
| At 2013-12-31 | 8,407,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 3,931,000 | USD | |
| At 2013-12-31 | 2,315,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 1,862,000 | USD | |
| At 2013-12-31 | 1,988,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 6,188,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 11,978,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 4,655,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 8,044,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 4,381,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 8,554,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 3,854,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 6,437,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 1,714,248 | shares | |
| At 2013-12-31 | 1,622,761 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-12-31 | 139,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 40,000 | USD | |
| At 2013-12-31 | 44,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 2,069,000 | USD | |
| At 2013-12-31 | 327,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 2,416,000 | USD | |
| At 2013-12-31 | 341,000 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -7,769,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -13,885,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -4,655,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -8,044,000 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 1,807,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 3,424,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 801,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 1,607,000 | USD | 181 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 22,000 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 23,000 | USD | 181 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -5,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -5,000 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | -385,000 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 525,000 | USD | 181 |
Inspect the source
- Entity
- Sage Therapeutics, Inc. / CIK 0001597553
- Captured
- 2026-09-21T17:20:16.999Z
- SEC response SHA-256
afd97550f2619e8ee699b816b1e9c9bfcb0395cfffc579f5c489401eae3ca58f
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001597553.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))